Typically, the benefits can be felt for about one to three months, after which another injection may be necessary to maintain optimal levels
While clinicians should not limit their usage due to cancer concerns, they must maintain a thorough surveillance for possible adverse outcomes
Even when using the arm consistently, move the injection site by at least 2.5 cm each time
In a new study reported in The Lancet, Tirzepatide, a GLP-1R/GIPR agonist, reduced alcohol's rewarding properties, locomotor stimulation, conditioned place preference, and accumbal dopamine release
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
The cascading effect can eventually cause organ failure if left untreated